J-and-A_Abt COVID cohorts_75D30120C08150 9.22.20.pdf

PDF 3 MB Posted

Attached to
COVID-19 Cohort Studies modifcation to contract Federal contract opportunity
Solicitation number
08150
Issued by
Department of Health and Human Services Centers for Disease Control and Prevention Office of Acquisition Services

View the file

On GovTribe

Work with this file on GovTribe

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Template for Justification and Approval for Other Than Full and Open Competition Completion Instructions: The Department of Health and Human Services (HHS) has established a standard template for the preparation of a J&A for Other Than Full and Open Competition. If this is an 8(a) set-aside, please note this form is not required unless the acquisition is valued (including all options) at greater than $22 million. This template is NOT applicable for actions using simplified acquisition procedures (FAR Part 13), Federal Supply Schedule orders (FAR 8.4) or task or delivery orders subject to fair opportunity (FAR 16.505).

Tailor all aspects of this template to the individual acquisition. Consult FAR Subpart 6.3 for guidance. An addendum may be added in case additional space is needed.

When this document is printed, the blue italic instructions are automatically deleted on the printed version.

JUSTIFICATION AND APPROVAL FOR OTHER THAN FULL AND OPEN COMPETITION

2. Description of Action:

Nature:

Pricing:

Funds:

3. Description of Services or Supplies:

Basis for Approval (FAR 6.303-1(d)):

As applicable, briefly describe the services or supplies required to meet the agency's needs, including make & model number where appropriate. Include quantities of supplies or period of performance for services. Provide information for any options included. If the action is a modification to an existing contract, distinguish clearly between the work covered by the original contract and the work to be obtained by the proposed modification.

4. Authority and Rationale: Identify the statutory authority, FAR title and FAR citation permitting other than full and open competition. It may be one of the following most commonly used citations by the operating divisions of the Department of Health and Human Services (HHS), but other exceptions may apply per FAR Subpart 6.3.

Actions other than simplified acquisition procedures (select only one and provide an explanation):

Explain why the intended contractor is the only responsible source who can provide the required supplies or services. Discuss the unique capabilities, expertise, etc. that support the lack of competition/why no other type of supplies or services will satisfy agency requirements. Explain factors/unique qualifications such as proprietary data or exclusive licensing rights, if applicable. When competition is limited to items particular to one manufacturer, this justification must explain why the particular brand name, product, or feature is essential to the Government's requirements, and that market research indicates other companies' similar products, or products lacking the particular feature, do not meet, or cannot be modified to meet the agency's needs in accordance with FAR 11.105. If in connection with a follow-on contract for continued development or production of highly specialized equipment, detail the substantial duplication of cost or unacceptable delays. May not Exceed one year, including all options, unless the head of the agency (Secretary of HHS) determines that exceptional circumstances apply.

If unusual and compelling urgency is the basis for the justification, explain the chronological events leading up to the requirement and explain why time constraints cannot permit even a limited competition. Describe the detrimental effects/serious injury to the mission of the requiring activity or to the government, financial or otherwise, that will result if this justification is not approved. Describe impact of required delivery/performance date. Describe the detrimental effects/serious injury to the mission of the requiring activity or to the government, financial or otherwise, that will result if this justification is not approved and the product or service cannot be provided by the intended sole source contractor. Failure to plan for expiring funds is not a valid reason for citing this exception. May not exceed one year, including all options, unless the head of the agency determines that exceptional circumstances apply.

Provide a citation to the statutory authorization and a brief description of its content, or identify the specified source or other agency.

Provide the authority and citation to the applicable section of FAR 6.3.

Provide a full explanation to justify use of the exception.

5. Agency Actions to Take or Remove Barriers That Led to Other Than Full and Open Competition (If applicable):

Describe the actions, if any, the agency may take to remove or overcome any barriers that led to the restricted consideration prior to any subsequent acquisition for the supplies of services is made. If no such actions have been taken, explain why.

6. Bridge Contracts:

For contract extensions or bridge contracts when a competitive follow-on is in the process of being developed, summarize history of current contract and explain the reasons for any delays in the acquisition. Include discussion of the milestones for the follow-on action; the milestones should be as efficient as possible. Discuss why it would be neither cost effective nor realistic to expect another contractor to perform during the brief interim period; include issues such as start-up costs, phase-in, transfer of GFP, recruitment and staffing, etc. If the action is because of a protest, provide a brief discussion of the protest including the date the protest was filed and the basis of the protest. Explain that the action will provide the minimum quantity or performance period.

7. Actions to Increase Competition:

Describe efforts made to compete the action, including whether a notice was or will be publicized as required by FAR Subpart 5.2 or which exception under FAR 5.202 applies. If a notice was publicized, discuss the number of written responses to the synopsis and the results of the assessment of the written responses. List sources, if any, that expressed, in writing, an interest in the acquisition. Provide rationale if interested sources were rejected. If applicable, state that no other sources have expressed interest, but all offers received shall be considered. Describe what actions will be taken to increase competition before subsequent acquisition of the supplies or services is required. You may state that an action is a one-time requirement, but if a similar requirement arises, every effort will be made to compete it to the maximum extent possible. If action is sole source because of proprietary data or licensing rights and there will be a continuing need for the requirement, there must be evidence that advanced planning has been initiated to overcome the barriers to competition, or there should be documentation to support an analysis that replacement costs/licensing purchase costs outweigh the benefits of competition. If the action is a contract extension or bridge, explain actions to compete the follow-on. If action is an urgent new requirement and a competitive follow-on is anticipated, explain that efforts are underway to facilitate a full and open competition.

8. Market Research:

Describe the extent of the market research conducted to identify all qualified sources and the results thereof. “Market Research” is defined as those attempts you made to ascertain whether other qualified sources exist, and can include contact with knowledgeable experts regarding similar or duplicate requirements, contact with industry, results of a sources sought synopsis, or draft solicitations. Research of the marketplace may consist of written, electronic (i.e. email) telephonic, or world wide web inquiries. Lack of advanced planning is not an acceptable reason for the lack of market research, but true urgency may necessitate abbreviated market research that is limited to readily available historical and commercial information. If action is a contract extension or bridge contract, describe the market research efforts underway or completed for the follow-on. See FAR 10.002(b)(2).

9. Procurement History:

Was action competed?

If action was not competed, state the cited authority, summarize rationale, and describe the actions that were supposed to be taken to increase competition and the results thereof:

10. Additional Information to support the justification:

If applicable, explain why technical packages or specifications to facilitate competition were not developed or available; describe actions taken to remedy the situation.

11. Technical / Requirements Certification: By my signature below, I certify that the supporting data included in this J&A is accurate and complete.

Program Manager Name:

Position Title:

Email address:

Phone:

Program Manager Supervisor (or one level above Program Manager) Name:

Position Title:

Email address:

Signature:

Date:

12. Fair and Reasonable Price/Cost Determination: As Contracting Officer, by my signature below, I hereby determine that the anticipated price/cost to the Government for this contract action will be fair and reasonable.

Provide the basis for this determination, e.g., describe techniques to be used to determine fair and reasonable price (FAR Subpart 15.402), such as price analysis, cost analysis, cost realism. Per FAR Subpart 15.403-4(a)(1), the threshold for obtaining cost or pricing data is $750,000.

Name:

Phone:

Signature:

Date:

13. Contracting Officer's Approval (Required for proposed contract not to exceed $700,000 (value calculated including all options)): I hereby certify that this justification is accurate and complete to the best of my knowledge. I approve this justification subject to availability of funds, and provided that the services and supplies herin describe have otherwise been authorized for acquisition.

Name:

Phone:

Signature:

Date:

14. Legal Review:

All J&As greater than $68 million must have a legal review from the General Law Division of the Office of the General Counsel prior to sending it to the Department.

15. OPDIV Competition Advocate Approval (Required for proposed contract over $700,000 but not exceeding $13.5 million value calculated including all options)):

I have reviewed this justification and find that it adequately supports other than full and open competition.

Name:

Phone:

Signature:

Date:

16. Office of Small and Disadvantaged Business Utilization:

I have reviewed this justification and find that it adequately supports other than full and open competition.

Name:

Phone:

Signature:

Date:

17. OPDIV HCA Approval (Required for proposed contract over $13.5 million but not exceeding $68 million value calculated including all options)):

Name:

Phone:

Signature:

Date:

18. Department Competition Advocate:

Concur:

Non-Concur:

Name:

Phone:

Signature:

Date:

(The below approval paragraph is required if the cumulative contract value, including all options, exceeds $68 million.)

19. HHS Senior Procurement Executive (SPE) Approval:

Based on the foregoing justification, I hereby approve other than full and open competition for the above stated procurement, subject to the availability of funds, and provided that the services herein described have otherwise been authorized for acquisition.

State supplies/services being procured:

State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304:

State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304 Name:

Phone:

Signature:

Date:

11.0.0.20130303.1.892433.887364 Justification & Approval - Other Than Full and Open Competition Health and Human Services Justification & Approval - Other Than Full and Open Competition

AcquisitionTitle: COVID-19 Cohort Studies - BAA Contract 75D30120C08150
Agency: CDC
NIHDrop:
PSCDrop:
PSCOther:
AcqusitionYear: 2020
Author: Mark Thompson, Research Epidemiologist
CheckBox4: 0
CheckBox5: 0
CheckBox1: 1
Purchase order/contract number:
CheckBox8: 0
CheckBox7: 0
CheckBox6: 1
CheckBox9: 0
Agency Actions to Take or Remove Barriers That Led to Fair Opportunity Exception (If applicable): This requirement was synopsized on Beta SAM for 15 days and no vendor submitted a capability statement for the requirement.
CheckBox10: 0
CheckBox11: 1
Other funds: Covid-19
TextField5: Abt Associates
TextField5: 6130 Executive Boulevard
TextField5: Rockville, MD 20852
CheckBox2: 1
CheckBox3: 0
TextField7:
As applicable, briefly describe the services or supplies required to meet the agency's needs, including make & model number where appropriate. Include quantities of supplies or period of performance for services. Provide information for any options included. If the action is a modification to an existing contract, distinguish clearly between the work covered by the basic order and the work to be obtained by the proposed modification.: Period of Performance: 09/08/2020-04/30/2021. Abt Associates was awarded (5/1/2020) a contract (75D30120C08150; “COVID-19 Cohort Studies”) to adapt multiple existing cohort studies to address critical knowledge gaps essential to inform public health policy decisions for the US response to the COVID-19 pandemic. Prospective cohorts are being conducted with healthcare personnel, first responders, households with children, and older adults. Common protocols and procedures have been finalized and approved by Institutional Review Boards to assess the incidence of symptomatic and asymptomatic SARS-CoV-2 infection using both molecular and serologic diagnostics. Enrollment using random stratified strategies are underway, and consented participants have completed electronic surveys and begun weekly active surveillance for COVID-19 using SMS text and REDCap data management systems that were customized to these cohorts. Methods for self-collection and shipping of respiratory specimens have been developed and approved by major carriers. All specimens are being shipped to a centralized molecular laboratory; specimen management and results reporting systems are implemented.

CDC requires that the shipping and supplies cost be increased in order to reflect the real costs now that FDA and carrier requirements are finalized. CDC also requires that cohorts be expanded in order to examine the effectiveness of licensed COVID-19 vaccines once they become available.

CheckBox12: 1
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: Because Abt Associates has completed all of the implementation tasks described above, they are the only contractor able to add expand operations of cohorts, including adding new participants. It is essential that there be continuity in methodology across cohorts consistent with procedures that Abt Associates has already established. It is also crucial that samples be increased by adding participants to existing cohorts rather than by initiating new studies in order for data to be comparable and collapsible.
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: NA
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: This requirement was synopsized on Beta SAM for 15 days and no vendor submitted a capability statement for the requirement.
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: Abt Associates is the only contractor able to add expand operations of cohorts, including adding new participants. It is essential that there be continuity in methodology across cohorts consistent with procedures that Abt Associates has already established. Given the work that has already been started through Abt Associates and its network of partners, it would not be possible for another vendor to enter the project at this time. This modification requirement was synopsized on Beta SAM for 15 days and no other vendor submitted a capability statement.
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: NA
State the full statutory authority and FAR cite and title, consistent with paragraph 4, e.g. 41 U.S.C. 3304: A cost & pricing analysis will be conducted on the contractors cost proposal. Abt Associates submitted certified cost & pricing data.
CheckBox13: 0
CheckBox14: 0
CheckBox15: 0
TextField9: 75D301-20-C-08150
CheckBox16: 1
CheckBox17: 0
Program Manager name: Lenee Blanton
Program Manager position title: Epidemiologist, Epidemiology and Prevention Branch, Influenza Division, NCIRD/CDC
Program Manager email address: ACY9@cdc.gov
Program Manager phone: 404-639-1400
Program Manager Supervisor name: Mark Thompson
Program Manager Supervisor position title: Deputy Branch Chief of Science, Epidemiology and Prevention Branch, Influenza Division, NCIRD/CDC
Program Manager Supervisor email address: isq8@cdc.gov
HHS Senior Procurement Executive (SPE) signature:
Program Manager Supervisor date: 2020-08-28
Contract Officer's Approval name: William Brannen
Contract Officer's Approval name: William Brannen
HHS Senior Procurement Executive (SPE) phone: 770-488-2084
HHS Senior Procurement Executive (SPE) phone: 770-488-2084
HHS Senior Procurement Executive (SPE) phone: 404-639-7291
Contract Officer's Approval date:
HHS Senior Procurement Executive (SPE) name: Sherry Smallwood
DateField6: 2020-09-01
Office of Small Business date:
OPDIV HCA date:
Concur with Acquisition: 0
Non-Concur with Acquisition: 0
HHS Senior Procurement Executive (SPE) date:
State supplies/services being procured: Period of Performance: 09/08/2020-04/30/2021. Abt Associates was awarded (5/1/2020) a contract (75D30120C08150; “COVID-19 Cohort Studies”) to adapt multiple existing cohort studies to address critical knowledge gaps essential to inform public health policy decisions for the US response to the COVID-19 pandemic. Prospective cohorts are being conducted with healthcare personnel, first responders, households with children, and older adults. Common protocols and procedures have been finalized and approved by Institutional Review Boards to assess the incidence of symptomatic and asymptomatic SARS-CoV-2 infection using both molecular and serologic diagnostics. Enrollment using random stratified strategies are underway, and consented participants have completed electronic surveys and begun weekly active surveillance for COVID-19 using SMS text and REDCap data management systems that were customized to these cohorts. Methods for self-collection and shipping of respiratory specimens have been developed and approved by major carriers. All specimens are being shipped to a centralized molecular laboratory; specimen management and results reporting systems are implemented.

CDC requires that the shipping and supplies cost be increased in order to reflect the real costs now that FDA and carrier requirements are finalized. CDC also requires that cohorts be expanded in order to examine the effectiveness of licensed COVID-19 vaccines once they become available.

File details come from the government source that posted it. Updated .